Boston—Anakinra may be an acceptable alternative to tocilizumab for treating cytokine release syndrome (CRS) after initial management with the latter agent, which continues to be in short supply due to its frequent use as a therapy for patients with severe COVID-19, a new study suggests.
The results are welcome news to pharmacists tasked with rationing tocilizumab (Kineret, Swedish Orphan Biovitrum) during the ongoing pandemic, the investigators reported during the 2022